From mint · Trisha Bhattacharya · · 1m 20s
Medanta Chairman's Pharma Panel Role Sparks Conflict Debate
Medanta's Naresh Trehan faces conflict of interest claims after joining government pharma marketing panel.
In brief
Medanta's Naresh Trehan faces conflict of interest claims after joining government pharma marketing panel. Advocacy group demands replacement of Medanta chairman Naresh Trehan from pharma marketing panel due to potential conflicts of interest. Originally reported by mint.
Medanta Chairman's Panel Appointment
Advocacy group questions Medanta chairman Naresh Trehan's inclusion in government pharma marketing panel.
“Medanta MD Naresh Trehan’s inclusion in pharma marketing panel is now being questioned by advocacy group over conflict-of-interest concerns”
Committee Composition
The panel includes former Union health secretary Preeti Sudan, NITI Aayog member M Srinivas, and Medanta chairman Naresh Trehan.
Committee's Mandate
The committee must examine current monitoring systems and recommend changes to improve transparency and compliance within two months.
Advocacy Group's Concerns
Group cites 2018 NPPA reports on overcharging at Medanta hospitals as reason for potential conflict of interest.
“NPPA”
Conflict of Interest Claims
Group argues Trehan's financial interests could affect committee's impartiality in pharma regulation decisions.
Government Response
Department has not yet replaced Trehan despite group's objections to committee's independence.
Panel's Impact
Committee's recommendations could shape pharma marketing oversight in India's healthcare system.
Current Status
Group has asked government to reconstitute panel to ensure independence from potential conflicts.
Regulatory Context
India's pharma marketing rules were updated in 2024 to strengthen implementation framework after 2015 voluntary code.
“UCPMP 2024”
At a glance
Advocacy group demands replacement of Medanta chairman Naresh Trehan from pharma marketing panel due to potential conflicts of interest.
